OKYO Pharma Limited Sponsored ADR (OKYO) Stock Price & Analysis

OKYO Stock Chart & Stats

$1.39-$0.08(-5.44%)

At close: Nov 02 11:09 AM EST

Day’s Range: $1.36 - $1.50
52-Week Range: $1.26 - $3.20
Previous Close: $1.47
Volume: N/A
Average Volume (3M): 57.53K
Market Cap: $77.14M
Enterprise Value: $56.20T
Total Cash (Recent Filing): $20.59M
Total Debt (Recent Filing): $0
Price to Earnings (P/E): ―
Beta: 0.24
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Clarity For Phase 3

Direct FDA alignment on a single-dose Phase 3 registrational design materially reduces program regulatory risk. This durable regulatory clarity supports an efficient pivotal path, increases likelihood of a streamlined review, and meaningfully de-risks time-to-market and strategic planning for the lead asset.

Sufficient Near-term Funding

A ~ $20M cash balance after a $25M raise provides a multi-quarter runway specifically tied to executing the FDA-agreed Phase 3 NEPTUNE trial. This funding reduces immediate financing risk and allows management to focus on clinical execution and regulatory milestones rather than urgent capital raises.

Low Financial Leverage

Minimal debt minimizes fixed obligations and interest burden during a multi-year development cycle. Low leverage preserves financial flexibility for future capital raises or partnerships, lowering insolvency risk while the company funds late-stage trials and seeks regulatory outcomes.

Bears Say

Pre-revenue Profile

As a development-stage biotech with zero product revenue, long-term value depends entirely on clinical success, approvals, or non-dilutive partnerships. This structural absence of operating income means ongoing reliance on capital markets or deals until commercialization, elevating execution and financing risk.

Persistent Negative Cash Flow

Consistent negative operating and free cash flow reflect ongoing R&D and trial costs, creating a durable funding need. Volatile burn rates complicate planning and may necessitate future dilution or partnership terms that dilute existing shareholders or constrain strategic choices if trial timelines extend or costs rise.

Prior Balance-sheet Strain

A recent history of negative equity signals past capital shortfalls and dilution events, which can limit strategic flexibility. Although equity improved in FY2026, the prior instability highlights vulnerability to financing cycles and underscores that balance-sheet strength remains contingent on successful trial execution and prudent cash management.

OKYO Pharma Limited Sponsored ADR News

Analyst Reaffirms Buy on OKYO as Urcosimod Enters Pivotal Phase 3; $5 Price Target Maintained

OKYO Pharma Limited Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock

4w agoOKYO

OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On October 6, 2026, OKYO Pharma announced that the first patients have been enrolled in its Phase 3

4w ago6K OKYO

Okyo Pharma announces first patients enrolled in NEPTUNE trial

Okyo Pharma (OKYO) announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain, or NCP. Published first on TheFly – the ultimate source for real-time,

4w agoOKYO

OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Key Ophthalmic Conferences

An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. OKYO Pharma Limited, a clinical-stage biopharmaceutical company targeting neuropathic corneal pain and anterior segment eye diseases,

1M ago6K OKYO

OKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. OKYO Pharma Limited plans to present at the Ophthalmology Futures European Forum in London on September 10, 2026,

1M ago6K OKYO

OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. OKYO Pharma Limited announced on September 8, 2026, that it will take part in a fireside chat at

1M ago6K OKYO

Okyo Pharma management to meet virtually with Piper Sandler

Virtual Meeting to be held on August 25-26 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s

2M agoOKYO

OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial

An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. OKYO Pharma reported on July 28, 2026, that its Chief Scientific Officer, Raj Patil, purchased 3,363

3M ago6K OKYO

Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49

Okyo Pharma (OKYO) announced that Raj Patil, chief scientific officer of Okyo Pharma has increased his holdings with the purchase of 3,363 of the company’s ordinary shares on Nasdaq at

3M agoOKYO

OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases.

3M ago6K OKYO

OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an announcement. On July 23, 2026, OKYO Pharma announced that non-executive director John Brancaccio purchased 5,000 ordinary shares on Nasdaq

3M ago6K OKYO

Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38

OKYO Pharma (OKYO)announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201

3M agoOKYO

Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54

Okyo Pharma (OKYO) announced that Okyo Pharma’s CEO, Robert Dempsey, has purchased 15,000 of the company’s ordinary shares on Nasdaq at $1.54 per share. Published first on TheFly – the

3M agoOKYO

OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On July 23, 2026, OKYO Pharma announced that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares

3M ago6K OKYO

OKYO FAQ

What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?

OKYO Pharma Limited Sponsored ADR lowest stock price was $1.26 and its highest was $3.20 in the past 12 months.

What is OKYO Pharma Limited Sponsored ADR’s market cap?

OKYO Pharma Limited Sponsored ADR’s market cap is $77.14M.

When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?

OKYO Pharma Limited Sponsored ADR’s next earnings report is estimated for Jul 30, 2024 (not yet confirmed), which is 827 days ago.

How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?

OKYO Pharma Limited Sponsored ADR released its earnings results on Aug 05, 2025. The company reported -$0.04 earnings per share for the quarter.

Is OKYO Pharma Limited Sponsored ADR overvalued?

According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued.

Does OKYO Pharma Limited Sponsored ADR pay dividends?

OKYO Pharma Limited Sponsored ADR does not currently pay dividends.

What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?

OKYO Pharma Limited Sponsored ADR’s EPS estimate is -0.09.

How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?

OKYO Pharma Limited Sponsored ADR has 52,479,527 shares outstanding.

What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?

OKYO Pharma Limited Sponsored ADR reported an EPS of -$0.04 in its last earnings report. Following the earnings report the stock price went up 1.603%.

Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?

Hedge funds hold OKYO Pharma Limited Sponsored ADR shares: the largest hedge-fund position in OKYO Pharma Limited Sponsored ADR is 70,131,081 shares, and hedge funds increased their holdings by 578.0 shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

OKYO Pharma Limited Sponsored ADR Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description